Risk to Overseas Business Expansion from Changes in Foreign Laws, Tax Systems and Pharmaceutical Administration
First written in FY2016. 18 of 20 entries say "Restated". Latest entry: FY2024-Q2.
Zeria Pharmaceutical moved to the "Worse" side of this theme in 2023, 2 years after the typical company in this theme (2021).
The whole theme swung hardest in 2025: 46 of 93 companies on the "Worse" side.
28 other companies' latest entry also says "Materialised".
- FY2024-Q2MaterialisedAnnual report
「The amount was ¥5,327 million, down 9.6% year on year, due to higher expenses following a partial revision of the UK pharmaceutical price regulation system, as well as increases in sales promotion expenses and depreciation.」
It states that a review of the overseas pharmaceutical price regulation system was implemented in the UK and actually affected profit through higher expenses. - FY2023-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It explains that there have been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2023-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It explains that there have been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2023-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It explains that there have been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2022-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It was explained that there had been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2022-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It was explained that there had been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2022-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It explains that there have been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2020RestatedAnnual report
「When expanding our business overseas, changes in the laws, tax systems, pharmaceutical regulations and other rules of the countries and regions concerned may make the expected business expansion difficult or have a material impact on business profitability.」
Continuing to disclose the risk of changes in laws, tax systems and pharmaceutical regulations associated with overseas expansion. - FY2020-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It explains that there have been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2020-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It was explained that there had been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2019RestatedAnnual report
「When expanding our business overseas, changes in the laws, tax systems, pharmaceutical regulations and other rules of the countries and regions concerned may make the expected business expansion difficult or have a material impact on business profitability. For our group, which identifies the full-scale expansion of business in Asia as one of its management priorities, facing these circumstances may make it impossible to achieve the expected management results.」
Continuing to disclose the risk of changes in foreign laws, tax systems and pharmaceutical regulations associated with the full-scale expansion of the Asian business. - FY2019-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It was explained that there had been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2019-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It was explained that there had been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2019-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It explains that there have been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2018-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It explains that there have been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2017RestatedAnnual report
「When expanding our business overseas, changes in the laws, tax systems, pharmaceutical regulations and other rules of the countries and regions concerned may make the expected business expansion difficult or have a material impact on business profitability.」
Continuing to disclose the risk of changes in laws, tax systems and pharmaceutical regulations associated with overseas expansion, including in Asia. - FY2017-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It explains that there have been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2017-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It explains that there have been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2017-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It was explained that there had been no new developments or material changes regarding the risk to overseas business expansion from changes in foreign laws, tax systems and pharmaceutical regulations. - FY2016First statedAnnual report
「When expanding our business overseas, changes in the laws, tax systems, pharmaceutical regulations and other rules of the countries and regions concerned may make the expected business expansion difficult or have a material impact on business profitability.」
Described as a risk associated with the full-scale expansion of business in Asia.